XGN (Exagen) Moat Score: 4/10 (As of Jul. 06, 2026)


XGN Exagen Inc XGN
60 GF Score
Price $4.40
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Moat Score?

Exagen XGN -3.08% 60 Moat Score is 4 as of Jul. 06, 2026. GuruFocus rates XGN with a GF Score™ of 60/100 and a GF Value™ of $3.00 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Exagen ranks better than 82.95% on this metric.

Exagen has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Exagen has Narrow Moat: Exagen Inc has a modest moat based on its proprietary diagnostic tests and intellectual property. While it has some customer loyalty, it operates in a competitive market with limited pricing power and regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Exagen might have Narrow Moat - Discernible but modest moat.

Exagen  (NAS:XGN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Exagen Moat Score Related Terms

XGN vs BNR, IMDX, IDXG: Moat Score Comparison

For the Diagnostics & Research subindustry, Exagen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exagen Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Moat Score distribution charts can be found below:

* The bar in red indicates where Exagen's Moat Score falls into.


XGN
60GF Score
Exagen Inc XGN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Exagen (XGN) has a Moat Score of 4 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Exagen ranks #37 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 17.1%.
Is Exagen's Moat Score too high?
Exagen's current Moat Score is 4. Based on the distribution chart, Exagen ranks #37 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Exagen has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exagen's Moat Score compare to BNR and IMDX?
According to the Medical Diagnostics & Research industry distribution chart, Exagen ranks #37 out of 217 companies for Moat Score. This places Exagen in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Exagen's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exagen stock overvalued right now?
Based on GuruFocus' analysis, Exagen (XGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $4.40 — trading 46.7% above its estimated fair value. The current Moat Score is 4. Exagen's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Exagen (XGN), the current Moat Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.40 is trading 46.7% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Moat Score: 4
  • GF Value™: $3.00 vs. price of $4.40 (46.7% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
60GF Score

Get the complete analysis for XGN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.40
Price
$3.00
GF Value